brand-logo

Introducing eCTD Publishing Service

Introducing eCTD Publishing Service

Regulatory publishing demands are growing, and soon all submissions must be submitted in electronic CTD (eCTD) format.  In recognising this, Plunkett Consulting Group are excited by the opportunity to add regulatory publishing to our suite of services.  We have access to the Extedo eCTDmanager software that allows us to publish electronic regulatory documentation for not only Australia, but also international jurisdictions including Europe and US FDA.

Our staff have manage the publishing of many dossiers, and are proficient in preparing and publishing of regulatory files to the highest of standards.

Get in touch with us to discuss your publishing needs and how we can assist.

You might also like...​

You might also like...​

New Appointment Post – Sahar Bassal

New Appointment Post – Sahar Bassal One thing that we never lose sight of at Accelagen is that, on the end of every product, every trial, every protocol, every drug — is a patient. And it is our responsibility, and our privilege, to help our innovative global clients to translate ground-breaking science into meaningful gains […]

Read More
Accelagen team
New Appointment Post – Dominique

New Appointment Post – Dominique Wrangling kids down at Auskick and wrangling the many moving parts of a clinical trial is all in a day’s work for Accelagen’s new Clinical Project Manager, Dominique Holden. Bringing over 10 years’ experience in clinical research and an exemplary approach to trial management, Dominique was drawn to Accelagen’s reputation […]

Read More
Hands operating syringe
Accelagen accelerates time to market for European clients: Potentially best-in-class study for Treatment of BKV Infection sees exciting results

Accelagen accelerates time to market for European clients: Potentially best-in-class study for Treatment of BKV Infection sees exciting results Local CRO, Accelagen, attracts innovative European drug and antibody developers to trial in Australian market Engaged by world-renowned European clients and collaborators, Memo Therapeutics AG (“MTx”) based in Switzerland, and Vakzine Projekt Management GmbH (VPM) based […]

Read More